Article
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 2016
Héritier Sébastien, Emile Jean-François, Barkaoui Mohamed-Aziz, Thomas Caroline, Fraitag Sylvie, Boudjemaa Sabah, Renaud Florence, Moreau Anne, Peuchmaur Michel, Chassagne-Clément Catherine, Dijoud Frédérique, Rigau Valérie, Moshous Despina, Lambilliotte Anne, Mazingue Françoise, Kebaili Kamila, Miron Jean, Jeziorski Eric, Plat Geneviève, Aladjidi Nathalie, Ferster Alina, Pacquement Hélène, Galambrun Claire, Brugières Laurence, Leverger Guy, Mansuy Ludovic, Paillard Catherine, Deville Anne, Armari-Alla Corinne, Lutun Anne, Gillibert-Yvert Marion, Stephan Jean-Louis, Cohen-Aubart Fleur, Haroche Julien, Pellier Isabelle, Millot Frédéric, Lescoeur Brigitte, Gandemer Virginie, Bodemer Christine, Lacave Roger, Hélias-Rodzewicz Zofia, Taly Valérie, Geissmann Frédéric, Donadieu Jean
Abstract excerpt
PURPOSE: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia with a broad spectrum of clinical manifestations and outcomes in children. The somatic BRAF(V600E) mutation occurs frequently, but clinical significance remains to be determined. PATIENTS AND METHODS: BRAF(V600E) mutation was investigated in a French LCH cohort. We analyzed associations between mutation status and clinical...
Topics
- Adolescent
- Adrenal Cortex Hormones
- Antineoplastic Combined Chemotherapy Protocols
- Child